Gujarat Kidney and Super Speciality Limited operates healthcare facilities providing kidney-care, specialty medical, and hospital services. Rising healthcare expenditure and increasing demand for specialized treatment support long-term growth. Expansion of hospital capacity and specialized clinical services can increase patient reach. Medical expertise and local reputation can provide competitive advantages. Occupancy rates, doctor availability, regulatory requirements, treatment costs, and competition remain important considerations.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|
| ₹1,480 cr | ₹116 cr | ₹22 cr | 54.3 | 3.46 | 5.86 | 13.1% | 0.06 | ₹-15 cr | 53.2 | — |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 34 | 5 | 0.66 | — | — | 15.5% |
| Mar 2026 | 31 | 5 | 0.81 | — | — | 15.8% |
| Dec 2025 | 23 | 4 | 0.52 | — | — | 15.9% |
| Sep 2025 | 28 | 8 | 1.47 | — | — | 29.4% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | — Not assessable |
| EPS growth accelerating over 3 quarters | — Not assessable |
| Sales up 25%+, or sales growth accelerating | — Not assessable |
| Annual EPS up 25%+ in each of the last 2 years | — Not assessable |
| Net margin above the same quarter last year | — Not assessable |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Turtle | ✗ Close above the prior 55-session high · 209.80 ✗ Close above the prior 20-session high · 209.80 ✗ Close below the prior 20-session low · 169.93 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| Graham | ✗ Price at or below the Graham number · Graham number 49.94 ✗ P/E 15 or less · P/E 54.3 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 5.86 ✓ Current ratio 2 or more · 3.76 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 27/100 | Expensive |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GKSL this stock | +3.6 | +47.8 | +66.8 | — | — | — | 54.3 | 5.86 | 13.1 | — | — | 0.06 | 53.2 | 1,480 | 116 | 22 | 3.5 | — |
| BHAGERIA | +4.9 | +66.0 | +118.9 | +103.3 | +119.5 | +20.6 | 22.2 | 2.57 | 8.0 | 10.1 | — | 0.17 | 17.2 | 1,533 | 1,003 | 68 | 15.8 | 0.95 |
| INDOBORAX | -3.0 | -4.8 | +80.2 | +97.5 | +185.7 | — | 22.1 | 3.80 | 15.1 | 18.4 | — | 0.00 | 21.5 | 1,470 | 286 | 66 | 20.7 | 0.44 |
| ANTELOPUS | -9.2 | +16.4 | +63.8 | +92.3 | — | — | 26.6 | 5.38 | 15.9 | 21.4 | — | 0.00 | 21.0 | 3,525 | 359 | 133 | 37.8 | -0.32 |
| NGLFINE | +0.2 | -7.9 | +20.6 | +82.7 | +48.7 | — | 29.9 | 5.20 | 15.7 | 17.1 | — | 0.33 | 20.9 | 1,713 | 536 | 57 | 92.6 | 1.28 |
| RAIN | +8.3 | +5.7 | +68.3 | +77.6 | +37.5 | -7.8 | 14.0 | 0.94 | 0.6 | 8.2 | — | 1.35 | 5.8 | 7,537 | 18,464 | 667 | 16.0 | 1.42 |
| APCOTEXIND | -6.3 | +2.7 | +44.8 | +56.5 | +9.9 | +39.2 | 18.2 | 4.73 | 17.3 | 20.1 | — | 0.15 | 16.1 | 2,939 | 1,591 | 161 | 31.1 | 0.94 |
| OCCLLTD | +23.5 | +40.2 | +93.8 | +53.5 | — | — | 12.7 | 2.20 | 11.5 | 12.5 | — | 0.20 | 11.8 | 950 | 602 | 75 | 15.0 | 1.08 |
| IGPL | +2.3 | +31.2 | +32.9 | +35.8 | +8.7 | -32.7 | 21.2 | 1.30 | 0.2 | 3.1 | — | 0.27 | 17.4 | 1,733 | 2,073 | 82 | 26.5 | 1.13 |
| KINGFA | +9.9 | +26.8 | +34.5 | +35.4 | +162.1 | +542.2 | 32.7 | 6.20 | 17.4 | 23.4 | — | 0.00 | 30.9 | 8,680 | 2,684 | 266 | 195.9 | 0.52 |
| VISHNU | -14.8 | -3.8 | +7.9 | +31.1 | +80.0 | +339.6 | 27.6 | 3.88 | 14.3 | 16.3 | — | 0.49 | 17.6 | 4,144 | 1,696 | 150 | 22.3 | 0.71 |